To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, we performed a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor-positive tumors displayed more hypermethylated loci than ER-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared to ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER-subtypes. Forty (32 novel, 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ERsubtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study demonstrates the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER-subtypes of breast cancer. Further, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups.
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INTRODUCTION
Approximately 200,000 women are diagnosed each year in the US with breast cancer, and nearly 50,000 die of their metastatic disease. Significant improvement made in both early detection and local/systemic therapy in the last few decades has significantly improved patient outcomes, especially survival. Breast cancers are characterized by their estrogen and progesterone receptor status (hereon termed ER), and it is established that ER expression (ER-positive) identifies a tumor phenotype with improved near/mid-term prognosis and likely benefit from adjuvant endocrine therapy when compared to ER-negative tumors. Yet, little is known about the genomic features within each ER-subtype of breast cancer that could explain why some patients with the same ER status have a good outcome while others do poorly regardless of treatment.
Current decision algorithms based on standard clinicopathologic factors (1) stratify ER-negative disease as having a high-risk for recurrence. (2-4) Although patients are now routinely offered adjuvant chemotherapy, most patients with node-negative, ER-negative disease remain disease-free after local therapy alone, including approximately 80% of ER-negative patients with tumors ≤ 1 cm (5) and up to 60% of all with stage 1 disease. (6) Consequently, there are patients with ER-negative disease that might do well without adjuvant chemotherapy and could avoid its potential toxicities, while others with a high residual risk despite it might be offered trials of novel therapies. Unfortunately, existing markers routinely used in clinical practice are of limited or no use in ER-negative patients (7) . For example, commonly used gene expression tests by RT-PCR have no clear prognostic/predictive utility in ERnegative disease (8, 9) and microarray assays developed so far appear to identify essentially all such patients as high risk (10, 11) , while other markers are still in development. Consequently, there is a critical need to develop better prognostic factors to improve assessment of residual risk and better predictive markers to optimize patient selection for standard and investigational systemic therapies.
Established clinically-annotated tissue banks from prospective randomized clinical trials and extensive databases on expression profiling in breast cancer in the last decade have allowed the prospective-retrospective development of the several prognostic and predictive tests. For instance,
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clinicians have come to accept foregoing adjuvant chemotherapy in patients with ER-positive, nodenegative disease with a low-risk risk of distant recurrence of <10% at 10 years according to the 21-gene expression profile Oncotype DX assay, while strongly recommending it in those with a residual risk > 20% despite 5 years of adjuvant tamoxifen (9) . Similarly useful tests are urgently needed for ERnegative breast cancer.
Multiple published studies using candidate gene approaches have suggested the utility of analyzing genes that undergo tumor-specific and promoter-specific hypermethylation as biomarkers for early detection and for prediction of outcome in multiple types of cancer (reviewed in 12). Methylated genes are particularly robust as biomarkers. In past studies, we developed a cancer detection panel using a quantitative cumulative methylation assay (QM-MSP) wherein the methylation status of multiple genes could be determined individually and cumulatively from picograms of input DNA, such as is retrieved from ductal lavage or ductoscopy (13, 14) and pathologic nipple discharge fluid (15) . We and others have found that methylated genes are frequently detected in the pre-invasive stage of DCIS (16) (17) (18) . Further, histopathologically normal ducts in the vicinity of tumor tissue display detectable hypermethylation of genes that are present in the adjacent DCIS or invasive cancer, while normal ducts present farther away do not (18) (19) (20) (21) . However, using the candidate marker approach it has been difficult to identify markers informative of the biology specifically of ER-positive or negative breast cancer or those that predict response to therapy, disease progression and survival. Therefore, we tested whether a genome-wide discovery platform would identify gene loci in tumors that better predict clinical outcomes (22) (23) (24) (25) (26) .
As the first step towards studies with clinical trial samples, we performed methylation array analyses on a discovery set of 103 primary invasive tumors and 21 normal samples. We found that distinctly different gene CpG loci typify the methylome of ER-positive and ER-negative breast cancers.
Forty gene loci were identified that stratified tumors according to ER-status. We also identified a putative "prognostic signature" of 100 CpG loci that are individually and collectively associated with outcome in patients with breast cancer. This feasibility study demonstrates that CpG locus methylation 5 and/or endocrine therapy).To identify methylated genes associated with ER status and their biology, a different approach was taken, emphasizing genes in which methylation changed dramatically between ER-positive and ER-negative samples. To achieve this, the initial selection was based on large fold changes. To evaluate the predictive capability of a panel of loci associated with ER status, we used independent samples to perform ROC analysis of a summary score of methylation derived as follows:
1) Methylation at each locus was standardized to have a common scale by subtracting the mean methylation level and dividing by the standard deviation for that locus, so that low methylation resulted in negative values, while high methylation gave positive values. 2) high methylation was associated with ER-positive status at some loci, and with ER-negative status at others, so standardized methylation scores for these latter loci were multiplied by -1, such that a high score uniformly indicated ER-positive samples; and 3) Genes were combined by averaging the standardized methylation scores for each patient, and the average score used in ROC analyses. The same procedure was used to summarize multi-locus homeobox panels associated with recurrence.
Validation in TCGA samples:
To verify that patterns of methylation observed in association with ER status and risk of recurrence within the JHU cohort were characteristic of breast cancer, we downloaded and analyzed data publicly available from the Cancer Genome Atlas Project (TCGA, http://tcga-data.nci.nih.gov/). We selected TCGA to perform this analysis since Illumina Meth27K was used, enabling direct comparisons for the same 50 bp CpG locus probes. In total, 185 samples were available on the Illumina 27k Human Methylation platform, and 465 samples were available on the Agilent G4502A expression array. Time to recurrence was not available at the time of download, but time to death was obtained for 342 of the samples queried on expression array and 182 samples queried on methylation array. Probe level data (TCGA level 2) was obtained for the methylation platform while gene-level summaries (TCGA level 3) were used for RNA expression. Rank-based Spearman correlations were calculated between methylation and expression using the 182 samples. Association between overall survival and methylation or expression was evaluated by Cox regression.
The ability of molecular markers to predict ER status was measured by performing an ROC analysis using the methylation and expression levels of individual genes as predictors and reporting the area under the ROC curve. For expression, the ROC analysis was based on the expectation of an inverse relationship between methylation and expression, so that in some cases, where a significant, positive association is observed between the two platforms, the area under the ROC may be substantially less than 0.5.
Quantitative-Multiplex Methylation-Specific PCR (QM-MSP):
The two-step multiplexed methylationspecific PCR method was previously described (15, 27, 28) . For AKR1B1 primers/probes see Supplemental Materials and Methods.
RESULTS
Methylation Profiling of Primary Invasive Breast Cancer Tumors
Whole-genome methylation array analysis was performed using the Illumina Infinium HumanMethylation27 BeadChip with primary invasive carcinoma samples (n=103), samples from microdissected normal breast tissue distant from the primary tumor (n=6), and epithelium enriched organoids isolated from normal breast (n=15). The array quantifies the proportion of methylated cytosines ( 5 mC) to total cytosines at each of 27,578 different CpG dinucleotides. The steps followed for our analysis is shown as a flowchart in Figure 1 .
To characterize the overall methylation profile of primary invasive breast tumors, unsupervised hierarchical cluster analysis using the Manhattan distance was performed on the most varied probes across tumors (1378 gene loci, SD>1.60) (Figure 2A ). Two distinct clusters of tumors were observed. 
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the ER-negative tumors (41/75; 55% of total). Given the importance of ER in breast cancer, it is not surprising to observe a strong association between predominant methylation patterns and ER status (odds ratio = 3.57, 95% C.I = 1.27-11.20, p-value = 0.082), but the result also highlights the importance of gene methylation in the disease process. The data also suggested additional subgroups within Clusters 1 and 2 with distinct methylation profiles such as Cluster 2B, which contains all ER-PR+ tumor samples.
Distinct groups of genes are specifically and recriprocally hypermethylated in ER-positive versus ER-negative breast cancer
Very little is known about the genomic features within each ER subtype of breast cancer that could explain why some patients have a good outcome while others will do poorly regardless of treatment. To determine the differences in breast cancer biology/behavior between ER subtypes, we characterized methylation patterns at 8376 selected CpG loci according to ER status. These loci met two criteria: 1) showed the most variation across primary tumors (SD >0.100) and 2) had probe detection p-values <0.0001 (indicating that DNA from that locus was present above background levels and that probe intensities were consistently measured across replicate beads; the distribution of methylation among these loci is shown in Supplemental Figure 1B) . A substantial number of loci were observed with median methylation levels ≥ 0.15 in both groups of tumor and normal breast organoids.
However, the majority of loci were more highly methylated in tumor than in normal organoid samples; 1744 loci in tumors had median methylation more than 2-fold higher compared to normal organoids (Supplemental Figure 1C To further refine this set to identify ER subtype-specific biological/molecular functions most driven by the epigenome in breast cancer, we selected a subgroup of 40 hypermethylated loci of the the 200 CpG locus set that individually showed the highest subtype specifity in individual tumor samples. Each individual locus was selected whose methylation profile demonstrated 1) robust reciprocal methylation between the two ER subtypes, 2) an incidence >20% of methylation within the breast cancer subtype and 3) low methylation in normal breast epithelium/stroma and leukocytes (β-value <0.15; Figure 3 ). Using these selection criteria, in the discovery set, we identified 27 loci/probes aberrantly and reciprocally hypermethylated in ER-positive tumors and 13 loci/probes aberrantly hypermethylated in ER-negative tumors. The majority of these were at loci newly identified as hypermethylated in breast cancer, and some never observed before as hypermethylated in cancer ( Table 2 ). As shown in Figure 3A , Supp Figure 2 and Supp Table 3 , ACADL, ADAMTSL1, ARFGAP3, B3GAT1, CDCA7, FAM78A, FAM89A, FLJ31951 (RNF145), FLJ34922 (SLFN11), GAS6, HAAO, HEY2, HOXB9, ITGA11, NETO, PROX1, PSAT1, RECK, SMOC1, SND1, and TNFSF9 were found hypermethylated almost exclusively in ER-positive tumors while, ADHFE1, DYNLRB2, HSD17B8, PDXK, PISD and WNK4 were found hypermethylated in ER-negative tumors. A number of genes previously reported as having subtype-specific methylation were also identified. EVI1, ETS1, IRF7, LYN, PTGS2 (COX2), RUNX3, and VIM were found to be hypermethylated in ER-positive tumors, while DAB2IP, HSD17B4, and PER1 were reported to be hypermethylated in ER-negative breast cancers (detailed information and references in Table 2B Figure 3B . Thus, many novel and some published gene loci were discovered that showed tumor-specific and ER-subtype specific hypermethylation. Existing literature provided further validity to our current observations.
External validation of methylation array findings in an independent test set of primary tumors.
Next we validated these findings in publicly available data on the breast cancer samples in TCGA (http://tcga-data.nci.nih.gov/) using an ROC analysis to evaluate predictive ability (Supplemental Table   2A ). The median area under the ROC curve for the 200 loci was 0.7; and one gene, SERPINA12, had an AUC of 0.95. In all, 156/200 ER probes yielded AUCs higher than 0.563, a range in which we expect only 5% of CpG loci by chance alone. Interestingly, expression of most of these same genes is also a very strong predictor of ER status. Here, 121 of the 175 unique genes from our ER panel and available on the expression array had areas under the curve exceeding the same 5% threshold. This is consistent with the high degree of correlation observed between expression and methylation measurements of these genes in the TCGA data. At an FDR of 0.05, 142 of 200 CpG loci are significantly inversely correlated with expression. And, as seen in Figure 3 , the TCGA data provided support for the existence of ER-subtype-specific methylation in breast cancer. To evaluate the predictive performance of the 40 locus panel ( Figure 2D ), we derived an average methylation score for the entire set as described in the Methods. Using this score ROC analysis demonstrated a high classification accuracy for the ER-subtype in TCGA data with an area under the ROC curve of 0.961, with a specificity of 89% at a sensitivity of 90% ( Figure 2D ; details in Supplemental Materials and Methods). A similar composite score derived from expression probes for the same genes showed some discriminatory ability in the TCGA data, albeit reduced, with an area under the ROC of 0.667 (data not shown).
CpG loci associated with disease progression in patients with newly diagnosed invasive breast cancer.
To develop an epigenomic signature that predicts outcome in patients with breast cancer, we conducted differential methylation analysis on primary tumors from recurrent versus non-recurrent GenomeStudio, using the DiffScore algorithm to compare tumors which later recurred to those which did not recur. The analysis was performed separately on the ER-positive and ER-negative tumor groups.
Candidate loci (50 per ER subtype) were selected meeting 3 criteria: 1) more highly methylated in recurrent tumors than in non-recurrent tumors, 2) relatively unmethylated in normal samples (β < 0.15), and 3) significantly differentially methylated above the false discovery rate cutoff (5%). Next we performed a multivariate Cox regression analysis for each of these candidate loci and generated Kaplan-Meier plots, showing the interrelationships between ER status and methylation and depicted in these plots as high/low with respect to the median methylation level for each CpG locus.
From these 100 candidate CpG loci, a set of 32, selected for high Cox coefficients (Supplemental Table   4A ), and visually striking Kaplan-Meier plots ( Figure 4 , Supplemental Figure 3 ) were followed up most closely, including with an extensive literature search to identify previous associations with outcome in breast cancer (Supplemental Table 4C ). Novel associations with poor outcome were identified for 1)
TMEM179, CRMP1 and SCNN1B in ER-positive breast cancer, 2) ALX1, COL14A1, EPHA5, EYA4, FLRT2, GPX7, KCNB2, LAMA1, LHX1, NEUROG1, POU3F2, AND STMN3 in ER-negative breast cancer, and 3) AKR1B1, COL6A2, EYA4, GPX7, HOXA13, HOXB13, NKX6-2, NRP2, POU4F2, REM1, and SLITRK2, in both ER-positive and ER-negative tumors. Cox regression p-values for each member of the 100 CpG loci set is presented in Supp Table 4A . Since the differential methylation analysis was designed in such a way to find loci most highly methylated in recurrent tumors, we did not observe hypomethylated loci associating with recurrence.
To verify array data using an independent assay, and to ensure future technical translation of the HumanMethylation27 array data to laboratory assays, we tested several methylated genes, such as EVI1, DAB2IP and AKR1B1 by performing Quantitative Multiplex-Methylation Specific PCR (QM- Table 4A ). With only 375 homeobox loci (189 genes) present in the 27,578 loci (14,495 genes) array, this represented a dramatic enrichment of homeobox genes in our 100 loci recurrence related set (odds ratio = 16.17, p = 6.515e-13). These data clearly implicate methylated homeobox genes as key factors in tumor progression. To determine if the other homeobox loci on the array exhibited similar methylation patterns, we extended our analysis to 60 homeobox loci which showed high variance (SD above the 95th percentile for the array) among the tumors, excluding the 18 loci represented in the recurrence sets. 2D-hierarchial cluster analysis (using the Manhattan distance) was performed to characterize these loci. As shown in the heatmap in Figure 5 
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Next we sought to validate these findings in publicly available TCGA breast cancer samples (http://tcgadata.nci.nih.gov/), using Cox regression to evaluate association between methylation and overall survival; progression free survival was not available for these samples at the time of download. In total, survival information was available for 342 of the samples available on expression array, of which 182 were also available on methylation array. Despite the change of outcome variable and moderate sample sizes, results in TCGA data as a set confirmed the findings that these genes are significantly associated with outcome. An overwhelming majority of our recurrence marker loci (78/100) have positive Cox regression coefficients, indicating that hypermethylation of these loci is associated with a worse outcome in these samples as well. By comparison, we would expect only half of these loci to have positive Cox coefficients by chance alone, giving a composite p-value of 2.2e-09, in support of the association. Additional confirmation for the panel is provided by the fact that for more than 2/3 of these genes, Cox regression analysis of TCGA expression data shows that low expression correlates with worse outcome. This result is wholly consistent with the observed methylation results, and statistically significant in its own right, with a p-value of 0.00022. This is consistent with the high degree of correlation observed between expression and methylation measurements of these genes in the TCGA data. At an FDR of 0.05, 43 of 100 CpG loci are significantly inversely correlated with expression. We also performed a multivariate Cox regression analysis for each of these candidate loci and generated Kaplan-Meier plots for the sets of 18 loci (log rank test p-value 0.00027) and 60 loci (log rank test pvalue 0.00036), compared to the top 5% of varied probes (1378 probes, p-value 0.112), demonstrating significant interrelationships between homeobox gene methylation and survival (data not shown).
Discussion
In this study, we report the results of a genome wide array analysis of primary invasive breast cancers of 27,578 CpG loci. This screen identified hypermethylated genes that specifically segregate with ER-positive or ER-negative tumor subtypes, which were then validated in silico using the newly populated TCGA breast cancer database. The array analysis also identified 100 gene loci that were enriched for homeobox-containing genes and predicted recurrence in breast cancers. Many novel hypermethylated loci were identified. In summary, we demonstrate that the methylome is a rich source of genes whose hypermethylation has the potential to significantly contribute to the understanding of ER-subgroups of breast cancer and predict recurrence in ER-positive and in ER-negative breast cancers.
We observed a significantly higher frequency of hypermethyation in ER-positive compared to Figure   3A , B), shedding light on many novel pathways and constituent genes that may be involved in the genesis of these subgroups. We tested the strength of these observations using an independent dataset from TCGA for both methylation and expression. All 40 CpG loci showed reproducible associations with ER-subtype and these markers classified essentially all tumors into the correct ER subtype (AUC 0.961). Interestingly, expression of the same genes was also found to be a very strong predictor of ER status. Thus, independent TCGA data strongly validated our findings. With the caveat 14 that both the discovery and validation cohorts represent small sample sets, the reproducibility of the findings supports the strength of this platform to reveal differences that can now be studied in detail.
A major goal of our work is to find markers that can prognosticate recurrence and predict benefit from therapy. Expression array-based analyses have proven to be useful for ER-positive breast cancers (30, 31) . Their utility, however, has been limited in ER-negative breast cancer. Also, DNA mutation and copy number studies have been found less useful in breast cancer compared to other cancers (eg. lung and colon), probably reflecting the greater diversity of breast cancer subtypes (32) (33) (34) . Epigenetically mediated gene silencing through DNA methylation occurs extremely frequently and has now been accepted as a major driver in neoplastic transformation, especially in the breast (12) .
Genome-wide methylation analysis allowed us to identify a tumor recurrence marker set of 100 gene loci; a few specific to ER-positive, many loci specific to ER-negative tumors and many common to both (Figure 4 , Supplemental Table 4C ). The emergence of a homeobox gene-methylation signature predictive of recurrence among the 100 recurrence loci and also among all homeobox loci on the array is notable. Substantial inverse correlation was seen between methylation and expression of the genes, both of the ER-stratifying set and the recurrence set of CpG loci, suggesting functional relevance to the effects of methylated genes observed in our study. These genes play critical roles in differentiation and development, growth factor receptor signaling, angiogenesis and more recently an unequivocal role in stem cell function [reviewed in (35) hypermethylated in (A) ER+ breast cancers, (B) ER-negative breast cancers and, (C) loci previously known to be associated with ER-status are shown. A total of 21 additional samples were arrayed and used for ER classification, but not for outcome analyses. These 21 cases were excluded from the outcome analysis for the following reasons: Neoadjuvant treatment (n = 8); Samples obtained 6 months after the initial diagnosis (n=10); progression within 6 month after diagnosis (n=10). 1A4 1B23  1C1 1D3 1D9  1F12 1F24 1G16 1G6  1H6 2A1 2B20 2B24 2C13 2H21 3A15 817 872 7109 7121 7144  1B20 1C23  1E  17 2B22  2C2 2C6 805 829 832 836 847 856 867 873 876 7113 7117 7142  1A18 1A24 1B16  1B9 1C10  1E  11 1F9 1H18  1H2 1H3 2A17 2C18  2C4 803 
